Dear Colleague,
It’s our pleasure to announce we are now organizing Melanoma and Immunotherapy Bridge 2025, on behalf of Fondazione Melanoma Onlus.
Upcoming annual appointments for worldwide cancer clinicians and researchers, gaining more and more attendees every year, the 11th edition of Immunotherapy Bridge and the 16th edition of Melanoma Bridge will be held in Naples (Italy) from December 3rd to 4th and from December 4th to 6th, respectively.
The first session of Immunotherapy Bridge will be jointly organized with the Society for ImmunoTherapy of Cancer and dedicated to the novel immune biology and Cell Therapy. An in depth analysis of the trends in immunotherapy in various type of cancers, the novel drugs beyond checkpoints and T-cells an the drivers of organ specific immune response will follow.
The scientific program of Melanoma Bridge will be dedicated to the most pressing of the unanswered questions, the applicability of melanoma as a model system, the mechanisms of resistance and the most valuable emerging strategies.
Both Immunotherapy and Melanoma Bridge meetings will host a “Great Debate” session, where counterpoint views from leading experts on specific controversial clinical issues will be presented, discussed and evaluated by the audience.
Attendees are expected from all around the world and encouraged to submit their abstracts for posters or oral communications during the meetings. The speaker of the abstracts selected for oral communication will be exempt from registration fee and invited as speaker to Naples.
We’re looking forward to meeting you again in Naples!
Paolo A. Ascierto
Corrado Caracò
Leisha A. Emens
Bernard A. Fox
Iman Osman
Igor Puzanov
The Immunotherapy Bridge will start with a Session jointly organized with SITC on TIL Advancements, CAR-T and TILs.
Hence, we will discuss the state of the art of immunotherapy beyond T cells, novel approches for immune monitoring and the organ specific immune response to share what different cancers teach about the general understanding of malignancies. The final session will be focused on neoadjuvant therapies across cancers.
Immunotherapy Bridge will end with the Great Debate Sessions, in which the most important issues from clinical practice and research will be shown and exhaustively discussed from two different points of view.
This year latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment will be discussed in the sessions dedicated to the translational research in melanoma, tumor biology, melanoma brain metastases and emergent strategies on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.
Then, the Great Debate sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view.
